Schizophrenia
Conditions
Interventions
The study drug is metformin. Intervention group will be given metformin and the control group a similar appearing placebo one tablet tds.
Intervention group Metformin dose- commencing dose 250mg b.d.
Sponsors
Faculty of Medicine
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with schizophrenia or schizoaffective disorder according to ICD-10 research criteria 2.Age > 18 years 3.Treated with olanzapine, risperidone or clozapine 4. Gained more than 10% of the pre treatment body weight
Exclusion criteria
Exclusion criteria: 1. Those concurrently treated with other psychotropics known to cause weight gain, (lithium carbonate, carbamazepine, sodium valproate and antidepressants) 2. Patients too ill to consent 3. Patients previously diagnosed with diabetes 4. Pregnant patients 5. Patients with impaired renal functions before enrollment (Sample size calculation is based on an expected difference in weight of Body Weight Gain of between the 2 groups, a power of 80%, and a Type I error of 5%. Sample size required in each group=64)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in total body weight [Baseline, 12 weeks and 24 weeks] | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index (BMI), waist/hip ratio, fasting blood sugar, lipid profile [Baseline, 12 weeks and 24 weeks] | — |
Countries
Sri Lanka
Contacts
Public ContactDr. Varuni de Silva
Senior Lecturer in Psychiatry
Outcome results
None listed